CCP Antibodies

Diagnostic Use

Anti-CCP (Cyclic Citrullinated Peptide) antibodies are present in approximately 70% of patients with rheumatoid arthritis and may predict more severe erosive disease.Rheumatoid arthritis (RA) is chronic inflammatory disease characterised by joint swelling, joint tenderness, and destruction of synovial joints, affecting approximately 0.5% of the world population. In 2010 the American College of Rheumatology and the European League against Rheumatism Collaborative classification criteria incorporated anti-CCP antibodies as one of the serological markers of RA. Anti-CCP antibodies have improved specificity compared to rheumatoid factor (RF) in the diagnosis of RA. On the basis of current evidence, testing for both rheumatoid factor and anti-CCP antibodies is recommended, in a patient with suspected rheumatoid arthritis.

Reference Intervals

Negative: <20 CU (Chemiluminescent Units)
Positive: ≥20 CU (Chemiluminescent Units)

Anti-CCP (IgG) detected using QUANTA Flash CCP3 (third generation CCP)
chemiluminescent assay at North Shore Laboratory. Anti-CCP values obtained with
different methods may not be used interchangeably.